Skip to main content
Top
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism

Authors: H. De Vitto, B. S. Mendonça, K. M. Elseth, A. Onul, J. Xue, B. J. Vesper, C. V. M. Gallo, F. D. Rumjanek, W. A. Paradise, J. A. Radosevich

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

Nutrient deprivation and reactive oxygen species (ROS) play an important role in breast cancer mitochondrial adaptation. Adaptations to these conditions allow cells to survive in the stressful microenvironment of the tumor bed. This study is directed at defining the consequences of High Nitric Oxide (HNO) exposure to mitochondria in human breast cancer cells. The breast cancer cell line BT-20 (parent) was adapted to HNO as previously reported, resulting in the BT-20-HNO cell line. Both cell lines were analyzed by a variety of methods including MTT, LDH leakage assay, DNA sequencing, and Western blot analysis. The LDH assay and the gene chip data showed that BT-20-HNO was more prone to use the glycolytic pathway than the parent cell line. The BT-20-HNO cells were also more resistant to the apoptotic inducing agent salinomycin, which suggests that p53 may be mutated in these cells. Polymerase chain reaction (PCR) followed by DNA sequencing of the p53 gene showed that it was, in fact, mutated at the DNA-binding site (L194F). Western blot analysis showed that p53 was significantly upregulated in these cells. These results suggest that free radicals, such as nitric oxide (NO), pressure human breast tumor cells to acquire an aggressive phenotype and resistance to apoptosis. These data collectively provide a mechanism by which the dysregulation of ROS in the mitochondria of breast cancer cells can result in DNA damage.
Literature
1.
go back to reference Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36. Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.
2.
go back to reference Moller P, et al. Air pollution, oxidative damage to DNA, and carcinogenesis. Cancer Lett. 2008;266(1):84–97.PubMedCrossRef Moller P, et al. Air pollution, oxidative damage to DNA, and carcinogenesis. Cancer Lett. 2008;266(1):84–97.PubMedCrossRef
3.
go back to reference Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625–34.PubMedCrossRef Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625–34.PubMedCrossRef
4.
go back to reference Paradise WA, et al. Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci. 2010;11(7):2715–45.PubMedCrossRef Paradise WA, et al. Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci. 2010;11(7):2715–45.PubMedCrossRef
5.
go back to reference Ralph SJ, et al. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation—why mitochondria are targets for cancer therapy. Mol Aspects Med. 2010;31(2):145–70.PubMedCrossRef Ralph SJ, et al. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation—why mitochondria are targets for cancer therapy. Mol Aspects Med. 2010;31(2):145–70.PubMedCrossRef
6.
go back to reference Jenkins DC, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995;92(10):4392–6.PubMedCrossRef Jenkins DC, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995;92(10):4392–6.PubMedCrossRef
7.
go back to reference Bentz BG, et al. The yin and yang of nitric oxide: reflections on the physiology and pathophysiology of NO. Head Neck. 2000;22(1):71–83.PubMedCrossRef Bentz BG, et al. The yin and yang of nitric oxide: reflections on the physiology and pathophysiology of NO. Head Neck. 2000;22(1):71–83.PubMedCrossRef
8.
go back to reference De Vitto H, Mendonça BS, Elseth KM, et. al. Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors (submitted in conjunction with current manuscript). Tumor Biol. 2012. doi:10.1007/s13277-012-0555-4. De Vitto H, Mendonça BS, Elseth KM, et. al. Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors (submitted in conjunction with current manuscript). Tumor Biol. 2012. doi:10.​1007/​s13277-012-0555-4.
9.
go back to reference Bentz BG, et al. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999;108(8):781–7.PubMed Bentz BG, et al. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999;108(8):781–7.PubMed
10.
go back to reference Radosevich JA, Elseth KM, Vesper BJ, et al. Long-term adaptation of lung tumor cell lines with increasing concentrations of nitric oxide donor. Open Lung Canc J. 2009;2:35–44.CrossRef Radosevich JA, Elseth KM, Vesper BJ, et al. Long-term adaptation of lung tumor cell lines with increasing concentrations of nitric oxide donor. Open Lung Canc J. 2009;2:35–44.CrossRef
11.
go back to reference Vesper BJ, et al. Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide. Tumor Biol. 2010;31(4):267–75.CrossRef Vesper BJ, et al. Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide. Tumor Biol. 2010;31(4):267–75.CrossRef
12.
go back to reference Yarmolyuk YR, et al. Part I. Development of a model system for studying nitric oxide in tumors: high nitric oxide-adapted head and neck squamous cell carcinoma cell lines. Tumor Biol. 2011;32(1):77–85.CrossRef Yarmolyuk YR, et al. Part I. Development of a model system for studying nitric oxide in tumors: high nitric oxide-adapted head and neck squamous cell carcinoma cell lines. Tumor Biol. 2011;32(1):77–85.CrossRef
13.
go back to reference Onul A, et al. Long-term adaptation of the human lung tumor cell line A549 to increasing concentrations of hydrogen peroxide. Tumor Biol. 2012; 33(3):739–48. Onul A, et al. Long-term adaptation of the human lung tumor cell line A549 to increasing concentrations of hydrogen peroxide. Tumor Biol. 2012; 33(3):739–48.
14.
go back to reference Scudellari M. Does mitochondrial dysfunction lie at the heart of common, complex diseases like cancer and autism? The Scientist. 2011;25:30–5. Scudellari M. Does mitochondrial dysfunction lie at the heart of common, complex diseases like cancer and autism? The Scientist. 2011;25:30–5.
15.
go back to reference Nelson DA, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 2004;18(17):2095–107.PubMedCrossRef Nelson DA, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 2004;18(17):2095–107.PubMedCrossRef
16.
go back to reference Samper E, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med. 2009;46(3):387–96.PubMedCrossRef Samper E, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med. 2009;46(3):387–96.PubMedCrossRef
17.
go back to reference Wong TS, et al. Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res. 2009;37(2):568–81.PubMedCrossRef Wong TS, et al. Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res. 2009;37(2):568–81.PubMedCrossRef
18.
go back to reference Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J Natl Cancer Inst. 1958;21(6):1131–47.PubMed Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J Natl Cancer Inst. 1958;21(6):1131–47.PubMed
19.
go back to reference Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65:55–63.CrossRef Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65:55–63.CrossRef
20.
go back to reference Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115(1):61–9.PubMedCrossRef Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115(1):61–9.PubMedCrossRef
21.
go back to reference Petitjean A, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–9.PubMedCrossRef Petitjean A, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–9.PubMedCrossRef
22.
go back to reference Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3(9):2303–8.PubMedCrossRef Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3(9):2303–8.PubMedCrossRef
23.
go back to reference Cubillos-Rojas M, et al. Simultaneous electrophoretic analysis of proteins of very high and low molecular mass using tris-acetate polyacrylamide gels. Electrophoresis. 2010;31(8):1318–21.PubMedCrossRef Cubillos-Rojas M, et al. Simultaneous electrophoretic analysis of proteins of very high and low molecular mass using tris-acetate polyacrylamide gels. Electrophoresis. 2010;31(8):1318–21.PubMedCrossRef
24.
25.
go back to reference Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–70.PubMed Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–70.PubMed
26.
go back to reference Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.PubMedCrossRef Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.PubMedCrossRef
27.
go back to reference Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20(1):51–6.PubMedCrossRef Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20(1):51–6.PubMedCrossRef
28.
go back to reference Rodriguez-Enriquez S, et al. Targeting of cancer energy metabolism. Mol Nutr Food Res. 2009;53(1):29–48.PubMedCrossRef Rodriguez-Enriquez S, et al. Targeting of cancer energy metabolism. Mol Nutr Food Res. 2009;53(1):29–48.PubMedCrossRef
29.
go back to reference Secomb TW, et al. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol. 1998;454:629–34.PubMedCrossRef Secomb TW, et al. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol. 1998;454:629–34.PubMedCrossRef
30.
go back to reference Fuchs D, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–9.PubMedCrossRef Fuchs D, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–9.PubMedCrossRef
31.
go back to reference Sablina AA, et al. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11(12):1306–13.PubMedCrossRef Sablina AA, et al. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11(12):1306–13.PubMedCrossRef
32.
go back to reference Kim KY, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011;413(1):80–6.PubMedCrossRef Kim KY, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011;413(1):80–6.PubMedCrossRef
33.
34.
go back to reference Olivier M, Hainaut P, Borresen-Dale A. Prognostic and predictive value of TP53 mutations in human cancer, in 25 years of p53 research. In: Hainaut P, Wiman K, editors. Springer; 2005. Olivier M, Hainaut P, Borresen-Dale A. Prognostic and predictive value of TP53 mutations in human cancer, in 25 years of p53 research. In: Hainaut P, Wiman K, editors. Springer; 2005.
35.
go back to reference Tomita Y, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006;281(13):8600–6.PubMedCrossRef Tomita Y, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006;281(13):8600–6.PubMedCrossRef
36.
go back to reference Hagn F, et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem. 2010;285(5):3439–50.PubMedCrossRef Hagn F, et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem. 2010;285(5):3439–50.PubMedCrossRef
37.
go back to reference Achanta G, et al. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005;24(19):3482–92.PubMedCrossRef Achanta G, et al. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005;24(19):3482–92.PubMedCrossRef
38.
39.
go back to reference Loibl S, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer. 2005;41(2):265–71.PubMedCrossRef Loibl S, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer. 2005;41(2):265–71.PubMedCrossRef
40.
go back to reference Chatterjee A, Mambo E, Sindransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25:4663–74.PubMedCrossRef Chatterjee A, Mambo E, Sindransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25:4663–74.PubMedCrossRef
41.
go back to reference Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19(7):802–15.PubMedCrossRef Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19(7):802–15.PubMedCrossRef
42.
go back to reference Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320:661–4.PubMedCrossRef Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320:661–4.PubMedCrossRef
43.
go back to reference Kulawiec M, Owens KM, Singh KK. mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice. J Hum Genet. 2009;54(11):647–54.PubMedCrossRef Kulawiec M, Owens KM, Singh KK. mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice. J Hum Genet. 2009;54(11):647–54.PubMedCrossRef
44.
go back to reference Gupta PB, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–59.PubMedCrossRef Gupta PB, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–59.PubMedCrossRef
45.
go back to reference Switzer CH, et al. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011;32(11):644–51.PubMedCrossRef Switzer CH, et al. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011;32(11):644–51.PubMedCrossRef
Metadata
Title
Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism
Authors
H. De Vitto
B. S. Mendonça
K. M. Elseth
A. Onul
J. Xue
B. J. Vesper
C. V. M. Gallo
F. D. Rumjanek
W. A. Paradise
J. A. Radosevich
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0564-3

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine